Skip to main content
SpringerLink
Log in

Chronic Kidney Disease

  • Chapter
Biomarkers of Cardiometabolic Risk, Inflammation and Disease

Abstract

The identification of reliable biomarkers of early kidney injury and of progression of the disease, as well as the identification of predictive biomarkers of morbidity and mortality, is an emergent area of research in the clinical area of nephrology. The more promising new biomarkers of kidney function, of the pathophysiological process underlying renal impairment, and of the associated cardiovascular risk are reviewed. Because inflammation is a common feature of kidney disease, inflammation as a risk factor and target for therapy in kidney disease will be also addressed and the inflammatory biomarkers reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80:806–21.

    Article  CAS  PubMed  Google Scholar 

  2. Lenz O, Fornoni A. Chronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey. BMC Med. 2006;4:30–9.

    Article  PubMed Central  PubMed  Google Scholar 

  3. KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Chapter 2: Definition, identification, and prediction of CKD progression. Kidney Int. 2013;3(suppl):63–72.

    Google Scholar 

  4. Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O, CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014;29:1037–47.

    Article  CAS  PubMed  Google Scholar 

  5. Junyent M, Martinez M, Borras M, et al. Usefulness of imaging techniques and novel biomarkers in the prediction of cardiovascular risk in patients with chronic kidney disease in Spain: the NEFRONA project. Nefrologia. 2010;30:119–26.

    CAS  PubMed  Google Scholar 

  6. Fliser D, Kollerits B, Neyer U, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–8.

    Article  CAS  PubMed  Google Scholar 

  7. Wheeler DC, Townend JN, Landray MJ. Cardiovascular risk factors in predialysis patients: baseline data from the Chronic Renal Impairment in Birmingham (CRIB) study. Kidney Int Suppl. 2003;84:S201–3.

    Article  PubMed  Google Scholar 

  8. Dajak M, Ignjatović S, Stojimirović B, Gajić S, Majkić-Singh N. Evaluation of renal damage by urinary beta-trace protein in patients with chronic kidney disease. Clin Lab. 2011;57:29–36.

    CAS  PubMed  Google Scholar 

  9. Matsushita K, Sang Y, Ballew SH, Astor BC, Hoogeveen RC, Solomon SD, Ballantyne CM, Woodward M, Coresh J. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014;34:1770–7.

    Article  CAS  PubMed  Google Scholar 

  10. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406–13.

    Article  CAS  PubMed  Google Scholar 

  11. Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fischer MJ, He J, Kallem RR, Kusek JW, Master SR, Miller ER 3rd, Rosas SE, Steigerwalt S, Tao K, Weir MR, Hsu CY; CRIC Study Investigators. Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015; 65(2):267–74.

    Google Scholar 

  12. Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, Shlipak MG. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis. 2012;60:904–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. van Timmeren MM, Vaidya VS, van Ree RM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2007;84:1625–30.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 1997;45:17–23.

    Article  CAS  PubMed  Google Scholar 

  15. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin (NGAL)-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57:1752–61.

    Article  CAS  PubMed  Google Scholar 

  16. Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K, Kimura K. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013;424:104–8.

    Article  CAS  PubMed  Google Scholar 

  17. Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006;284:175–82.

    Article  CAS  PubMed  Google Scholar 

  18. Yang J, Choi HM, Seo MY, Lee JY, Kim K, Jun H, Jung CW, Park KT, Kim MG, Jo SK, Cho W, Kim HK. Urine liver-type fatty acid-binding protein predicts graft outcome up to 2 years after kidney transplantation. Transplant Proc. 2014;46:376–80.

    Article  CAS  PubMed  Google Scholar 

  19. Hörstrup JH, Gehrmann M, Schneider B, Plöger A, Froese P, Schirop T, Kampf D, Frei U, Neumann R, Eckardt KU. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant. 2002;17:1005–13.

    Article  PubMed  Google Scholar 

  20. Hanamura K, Tojo A, Fujita T. Urinary and glomerular podocytes in patients with chronic kidney diseases. Clin Exp Nephrol. 2014;18:95–103.

    Article  CAS  PubMed  Google Scholar 

  21. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113–7.

    Article  CAS  PubMed  Google Scholar 

  22. Raptis V, Kapoulas S, Grekas D. Role of asymmetrical dimethylarginine in the progression of renal disease. Nephrology. 2013;18:11–21.

    Article  CAS  PubMed  Google Scholar 

  23. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev. 2010;6:82–90.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Eiselta J, Rajdlb D, Racekb J, Vostrýb M, Rulcováa K, Wirtha J. Asymmetric dimethylarginine and progression of chronic kidney disease – a one-year follow-up study. Kidney Blood Press Res. 2014;39:50–7.

    Article  Google Scholar 

  25. Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant. 2004;19:277–81.

    Article  PubMed  Google Scholar 

  26. Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, Miranda V, Faria MS, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28:268–75.

    Article  CAS  PubMed  Google Scholar 

  27. Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol. 2004;15:3184–91.

    Article  PubMed  Google Scholar 

  28. Keller C, Katz R, Cushman M, et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol. 2008;9:9.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Tonelli M, Sacks F, Pfeffer M, et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int. 2005;68:237–45.

    Article  CAS  PubMed  Google Scholar 

  30. Lin J, Hu FB, Rimm EB, et al. The association of serum lipids and inflammatory biomarkers with renal function in men with type II diabetes mellitus. Kidney Int. 2006;69:336–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Mallamaci F, Tripepi G, Cutrupi S, et al. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int. 2005;67:2330–7.

    Article  CAS  PubMed  Google Scholar 

  32. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int. 2005;68:766–72.

    Article  CAS  PubMed  Google Scholar 

  33. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.

    Article  CAS  PubMed  Google Scholar 

  34. Upadhyay A, Larson MG, Guo C-Y, Vasan RS, Lipinska I, O’Donnell CJ, Kathiresan S, Meigs JB, Keaney Jr JF, Rong J, Benjamin EJ, Fox CS. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant. 2011;26:920–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, Kurokawa K, Canaud B, Lameire N, Port FK, Pisoni RL. C-reactive protein and mortality in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron Clin Pract. 2011;117:c167–78.

    Article  CAS  PubMed  Google Scholar 

  36. Carrero JJ, Stenvinkel P. Inflammation in end-stage renal disease – what have we learned in 10 years? Semin Dial. 2010;23:498–509.

    Article  PubMed  Google Scholar 

  37. Witasp A, Rydén M, Carrero JJ, Qureshi AR, Nordfors L, Näslund E, Hammarqvist F, Arefin S, Kublickiene K, Stenvinkel P. Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS One. 2013;8(5):e63493.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Sanz AB, Izquierdo MC, Sanchez-Niño MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant. 2014;29 Suppl 1:i54–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Miyamoto T, Carrero JJ, Stenvinkelb P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens. 2011;20:662–8.

    Article  CAS  PubMed  Google Scholar 

  40. Hung AM, Ellis CD, Shintani A, Booker C, Ikizler TA. IL-1b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol. 2011;22:437–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  41. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2010;16:1652–61.

    Article  CAS  PubMed  Google Scholar 

  42. Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010;103:1154–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Jones SA, Fraser DJ, Fielding CA, Jones GW. Interleukin-6 in renal disease and therapy. Nephrol Dial Transplant. 2014. http://ndt.oxfordjournals.org/content/early/2014/07/09/ndt.gfu233.full.pdf+html.

  44. Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, Kaplan M, Chonchol M, Hakim RM. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial. J Am Soc Nephrol. 2014;25:623–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Ahmadi A, Mazooji N, Roozbeh J, Mazloom Z, Hasanzade J. Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients. Iran J Kidney Dis. 2013;7:461–7.

    PubMed  Google Scholar 

  46. Kirmizis D, Papagianni A, Belechri AM, Memmos D. Effects of vitamin E-coated membrane dialyser on markers of oxidative stress and inflammation in patients on chronic haemodialysis. Nephrol Dial Transplant. 2011;26:2296–301.

    Article  CAS  PubMed  Google Scholar 

  47. Deng J, Wu Q, Liao Y, Huo D, Yang Z. Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis. Nephrology. 2012;17:545–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments/Support

Authors thank the Portuguese Foundation for Science and Technology (FCT), COMPETE-FEDER and POPH/FSE, through the following support: PTDC/SAU-TOX/114253/2009 and UID/NEU/04539/2013 (CNC.IBILI).

Author information

Authors and Affiliations

  1. UCIBIO, REQUIMTE, Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, Porto, 4050-313, Portugal

    Alice Santos-Silva Ph.D. & Elísio Costa Ph.D.

  2. Universitary Nephrology Unit, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

    Rui Alves M.D., Ph.D.

Authors
  1. Alice Santos-Silva Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elísio Costa Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rui Alves M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alice Santos-Silva Ph.D. .

Editor information

Editors and Affiliations

  1. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Filipe Palavra

  2. Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Coimbra University, Coimbra, Portugal

    Flávio Reis

  3. Department of Internal Medicine – B, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

    Daniela Marado

  4. Interdisciplinary Centre of Research Egas Moniz, CiiEM, Caparica, Portugal

    Armando Sena

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Santos-Silva, A., Costa, E., Alves, R. (2015). Chronic Kidney Disease. In: Palavra, F., Reis, F., Marado, D., Sena, A. (eds) Biomarkers of Cardiometabolic Risk, Inflammation and Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-16018-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16018-4_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16017-7

  • Online ISBN: 978-3-319-16018-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation